Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.

Daniel Noerenberg Franziska Briest Cornelius Hennch Kenichi Yoshida Raphael Hablesreiter Yasuhide TakeuchiHiroo UenoAnnette M StaigerMarita ZiepertFazila AsmarBenjamin N Locher Erika TóthThomas WeberRose-Marie AminiWolfram KlapperMaria BouzaniViola PoeschelAndreas RosenwaldGerhard HeldElias CampoNaveed IshaqueKostas StamatopoulosGeorge KanellisIoannis AnagnostopoulosLars BullingerNeta GoldschmidtPier Luigi Luigi Zinzani Csaba Bödör Richard Rosenquist Theodoros P Vassilakopoulos German Ott Seishi Ogawa Frederik Damm

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

mutation analyses may guide treatment decisions between rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab.

Keyphrases

diffuse large b cell lymphoma
high dose
low dose
drug delivery
cancer therapy
lymph node
chronic lymphocytic leukemia
hodgkin lymphoma
combination therapy
replacement therapy